UNSPSC 51182700: Combination oral hypoglycemic agents

This classification denotes combination drugs and preparations which lower blood glucose levels, which patients can swallow by pill or liquid, and which therefore bear the term ORAL HYPOGLYCEMIC AGENTS. Practitioners deploy these agents against diabetes. Typical constituents are glimepiride, glipizide, glyburide, metformin, etc. Typical combination oral hypoglycemic agent constituents are glimepiride, glipizide, glyburide, and metformin.

UNSPSC 51182700 Combination oral hypoglycemic agents, a Class code, shows limited alignment with recent state and local procurement activity. The single posted opportunity under this code — Seminole County, Florida's IFB 60459723LAS — solicits naloxone and drug deactivation systems, which fall outside the pharmaceutical scope implied by the code's nominal designation. The mismatch suggests either a tagging error in the source data or a narrow use of the code for emergency response commodities rather than diabetes management pharmaceuticals. State and local buyers pursuing combination oral hypoglycemics would typically source through established pharmacy benefit managers, state Medicaid programs, or school district health services rather than competitive bidding processes; the naloxone procurement indicates the code as currently tagged in this jurisdiction reflects emergency response equipment, not chronic-disease medication.

Seminole County, Florida represents the only recent opportunity in the dataset under this code. The IFB, posted June 30, 2026 with a response deadline of July 26, 2023, calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, delivered quarterly to the Seminole County Community Health Building in Sanford, Florida. Bidders must include all shipping and delivery costs, comply with E-Verify requirements and drug-free workplace certification, maintain specified insurance coverage, and agree to a two-year initial term with a one-year renewal option. The potential FEMA funding introduces federal compliance obligations including the Clean Air Act and Federal Water Pollution Control Act. The code shows no geographic spread or repeat issuing-body activity across recent opportunities, and no established pattern of state or local procurement under this designation for its intended pharmaceutical purpose.